NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, Imatinib, a potent receptor tyrosine kinase inhibitor for treatment of chronic myeloid leukemia, was found to effectively reverse PVR in animal models of PAH and improved the hemodynamics and exercise capacity in PAH patients [20, 21].